Achieve Life Sciences (ACHV)
NASDAQ:ACHV
ACHV Stock Chart & Stats
$2.67
-$0.11(-3.08%)
At close: 4:00 PM EST
$2.67
-$0.11(-3.08%)
Day’s Range― - ―
52-Week Range$1.84 - $6.03
Previous CloseN/A
Volume131.37K
Average Volume (3M)597.92K
Market Cap
$142.15M
Enterprise Value$150.55M
Total Cash (Recent Filing)$36.40M
Total Debt (Recent Filing)$14.96M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
May 07, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding53,239,986
10 Day Avg. Volume1,109,755
30 Day Avg. Volume597,922
Financial Highlights & Ratios
PEG Ratio-4.92
Price to Book (P/B)10.07
Price to Sales (P/S)0.00
P/FCF Ratio-4.38
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-660.31
Enterprise Value/Ebitda-2.79
Forecast
1Y Price Target
$14.00Price Target Upside424.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.25
Revenue Forecast (FY)$15.10M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And SafetyLate-stage clinical trials showed substantially higher quit rates versus placebo and an encouraging tolerability profile for cytisinicline, supporting strong therapeutic potential and adoption prospects.
Competitive Positioning Versus ChantixPfizer's decision to distribute Chantix through a limited direct-to-consumer channel reduces the prospect of a heavily marketed rival, leaving clearer branded market positioning for cytisinicline if approved.
Patient Acceptance And Commercial DemandPost-trial surveys and open-label feedback reported high willingness to recommend cytisinicline, fewer cravings, and acceptance of reasonable co-pays, indicating meaningful real-world demand potential.
Bears Say
Generic CompetitionThe presence of multiple generic varenicline products establishes a low-cost competitive backdrop that could limit pricing power and market share for a new branded smoking-cessation therapy.
Supply Readiness And Launch TimingReliance on external manufacturers combined with limited management visibility into remediation creates ambiguity around supply readiness and could delay commercial launch planning.
Third-party Manufacturing InspectionAn FDA inspection at a listed contract manufacturer identified manufacturing-quality observations related to product chemistry and controls, which has weighed on the stock while remediation is ongoing.
Achieve Life Sciences News
ACHV FAQ
What was Achieve Life Sciences’s price range in the past 12 months?
Achieve Life Sciences lowest stock price was $1.84 and its highest was $6.03 in the past 12 months.
What is Achieve Life Sciences’s market cap?
Achieve Life Sciences’s market cap is $142.15M.
When is Achieve Life Sciences’s upcoming earnings report date?
Achieve Life Sciences’s upcoming earnings report date is May 07, 2026 which is in 36 days.
How were Achieve Life Sciences’s earnings last quarter?
Achieve Life Sciences released its earnings results on Mar 24, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.008.
Is Achieve Life Sciences overvalued?
According to Wall Street analysts Achieve Life Sciences’s price is currently Undervalued.
Does Achieve Life Sciences pay dividends?
Achieve Life Sciences does not currently pay dividends.
What is Achieve Life Sciences’s EPS estimate?
Achieve Life Sciences’s EPS estimate is -0.3.
How many shares outstanding does Achieve Life Sciences have?
Achieve Life Sciences has 53,239,986 shares outstanding.
What happened to Achieve Life Sciences’s price movement after its last earnings report?
Achieve Life Sciences reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went down -28.395%.
Which hedge fund is a major shareholder of Achieve Life Sciences?
Currently, no hedge funds are holding shares in ACHV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Achieve Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (424.34% Upside)
$14.00 (424.34% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 42.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.62%
12-Months-Change
Fundamentals
Return on Equity
-204.14%
Trailing 12-Months
Asset Growth
8.90%
Trailing 12-Months
Company Description
Achieve Life Sciences
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
ACHV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful progress on multiple strategic fronts: regulatory advancement (NDA acceptance and clear PDUFA date), an accelerated pathway for the vaping indication (CNPV), strong clinical and long-term tolerability data including peer-reviewed publication, commercial build-out using AI/digital capabilities, and steps to onshore manufacturing. Major risks highlighted include a limited cash balance relative to the current annualized burn (implying roughly an eight-month runway at current spend), GMP observations at a named manufacturer that introduce supply uncertainty, and the need for additional financing and payer access work ahead of a potential 1H 2027 launch. Overall, achievements and momentum around approval, clinical validation, and commercial preparation are substantial, but near-term financial and manufacturing risks are material and will require active management.View all ACHV earnings summariesACHV Stock 12 Month Forecast
Average Price Target
$14.00
▲(424.34% Upside)
Technical Analysis
Ownership Overview
1.68% Insiders
8.02% Mutual Funds
13.12% Other Institutional Investors
70.73% Public Companies and Individual Investors